5MJC BCU 13: Tyrosine Kinases as Targets for Cancer Therapy | Research To Practice
Pharmacology of Drugs: Nilotinib
Schematic representation of the mechanism of action of the BCR-ABLTKIs.... | Download Scientific Diagram
Nilotinib | C28H22F3N7O - PubChem
Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein | Leukemia
Nilotinib - Wikipedia
Nilotinib - Wikipedia
Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases - ScienceDirect
Frontiers | Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation | Oncology
CML therapy : post-Gleevec® era - ppt download
Mode of action of imatinib. The phosphorylation of a substrate is shown... | Download Scientific Diagram
Anti-Alpha-Synuclein Therapies in Parkinson's Disease - Practical Neurology
Frontiers | BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia | Oncology
Chronic Myeloid Leukemia - ppt video online download
Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer | EMBO Molecular Medicine
Current status of therapy for chronic myeloid leukemia: a review of drug development | Future Oncology
Modern Therapy of Chronic Myeloid Leukemia | IntechOpen
Third-line therapy for chronic myeloid leukemia: current status and future directions | Journal of Hematology & Oncology | Full Text
Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma
Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. - Abstract - Europe PMC
Enhanced in vivo targeting of estrogen receptor alpha signaling in murine mammary adenocarcinoma by nilotinib/rosuvastatin novel combination - ScienceDirect
An interesting commentary on the interpretation of the Nilotinib trial results – The Science of Parkinson's
Frontiers | A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease | Cellular Neuroscience
Proposed mechanism of nilotinib in the regulation of pigmentation.... | Download Scientific Diagram
Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events | Arteriosclerosis, Thrombosis, and Vascular Biology
